Share on StockTwits
 

Ariad Pharmaceuticals (NASDAQ:ARIA) was the target of unusually large options trading activity on Wednesday. Stock investors purchased 13,378 put options on the stock, American Banking & Market News reports. This is an increase of 129% compared to the typical volume of 5,844 put options.

ARIA has been the subject of a number of recent research reports. Analysts at UBS AG raised their price target on shares of Ariad Pharmaceuticals from $2.50 to $7.50 in a research note to investors on Monday. They now have a “neutral” rating on the stock. Separately, analysts at Citigroup Inc. downgraded shares of Ariad Pharmaceuticals from a “neutral” rating to a “sell” rating in a research note to investors on Monday. They now have a $5.50 price target on the stock, up previously from $2.50. Finally, analysts at Thomson Reuters/Verus downgraded shares of Ariad Pharmaceuticals from a “hold” rating to a “sell” rating in a research note to investors on Tuesday, December 24th. Five equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $6.86.

Shares of Ariad Pharmaceuticals (NASDAQ:ARIA) traded down 1.24% on Thursday, hitting $6.38. 5,018,203 shares of the company’s stock traded hands. Ariad Pharmaceuticals has a 1-year low of $2.15 and a 1-year high of $23.00. The stock’s 50-day moving average is $5.23 and its 200-day moving average is $12.37. The company’s market cap is $1.184 billion.

Ariad Pharmaceuticals (NASDAQ:ARIA) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.36) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.43) by $0.07. The company had revenue of $16.70 million for the quarter, compared to the consensus estimate of $16.67 million. During the same quarter last year, the company posted ($0.32) earnings per share. Ariad Pharmaceuticals’s revenue was up 1864.7% compared to the same quarter last year. Analysts expect that Ariad Pharmaceuticals will post $-1.55 EPS for the current fiscal year.

ARIAD Pharmaceuticals, Inc (NASDAQ:ARIA) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.